English corporate news

Peptonic Medical AB (publ) (the “Company”) announces that the Company has terminated its agreement with Mangold Fondförvaltning AB regarding the assignment as liquidity provider. The

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,

Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Company’s reconstruction plan, which was confirmed by the Uppsala District Court on 28 November

On 23 May 2025, PEPTONIC medical AB (“Peptonic” or the “Company”) issued a notice to the annual general meeting to be held on 26 June

Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Uppsala District Court has today, June 17 2025, approved the Company’s request to extend

Peptonic Medical AB (publ) (“Peptonic” or the “Company”) has today submitted a request to the Uppsala District Court to extend the ongoing company reconstruction by

In Peptonic Medical’s annual report for 2024, there was a remark in the audit report: “We draw attention to the administration report, which states that

The 2024 Annual report of Peptonic Medical AB (publ) is now available on the company website. The annual report is available in Swedish in PDF

PEPTONIC medical AB (publ) (the “Company”) has, as previously communicated, applied for and been granted corporate restructuring by the Uppsala District Court. At the creditors’

N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the annual general meeting in PEPTONIC medical AB,

Correction of the press release published on 7 May 2025 regarding the resolution from the extraordinary general meeting on 7 January 2025 on the reduction

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,

As communicated through a press release on March 11, 2025, the board of directors of PEPTONIC Medical AB (publ) (the “Company”) decided to submit an

As part of its growth strategy in the US market, Peptonic Medical AB (publ) (“Peptonic” or the “Company”) has established a new wholly-owned subsidiary, Peptonic

Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the press release issued on March 14, 2025, titled “Court of Appeal convicts former employees

Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Court of Appeal has overturned the District Court’s acquittal in the insider trading case

Peptonic Medical AB (publ.) (“Peptonic” or “the Company”) announces that the Uppsala District Court has approved the Company’s application for corporate restructuring. This decision enables

The Board of Directors of Peptonic Medical AB (publ.) (“Peptonic” or “the Company”) has today decided to submit an application for corporate restructuring. This decision

Peptonic Medical AB (publ) (“Peptonic” or the “Company”) is adjusting its organization following the structural changes implemented in 2024. As part of this process, the

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,

Peptonic Medical AB (publ) (“Peptonic” or “the Company”) is thrilled to announce the highly anticipated U.S. launch of its portfolio of intimate care products under

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,

Peptonic Medical (publ) (“Peptonic” or “the Company”) has had a highly successful launch of VagiVital Intimate Calming Gel in Sweden, with nearly 1,000 units sold

Peptonic Medical (publ) (“Peptonic” or “the Company”) announces the launch of VagiVital Intimate Calming Gel, a specially developed product that provides immediate moisture while relieving

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,

Peptonic Medical AB (publ) (“Peptonic” or “the Company”) announces the successful launch of its in-house developed lubricant, VagiVital Active Glide, at the turn of the

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,

Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the United States Patent and Trademark Office (“USPTO”) has granted a patent for the relief

The extraordinary general meeting of PEPTONIC medical AB, reg. no. 556776-3064 (the “Company”), was held today on 7 January 2025. The meeting resolved, with the

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,